Amr E Abbas, Luai Madanat, Houman Khalili, Ramy Mando, Mazhed Kheyrbek, Rohit Chandra, Shailesh Niroula, Ivan Hanson, Simon Dixon, Brian Renard, Richard Bloomingdale, Elvis Cami, Brittany Pridham, Jeffrey Altshuler, Bogdan Kindzelski, Franco Fazzalari, Francis Shannon, Alessandro Vivacqua
On 7/31/2023, the Trifecta valve was withdrawn from the market following concerns regarding early (≤ 5 years) structural valve deterioration (SVD) mainly as aortic regurgitation (AR). Our aim was to determine the timing, mechanism, and impact of bioprosthetic SVD in patients undergoing redo aortic valve replacement (Redo-AVR) with either redo-SAVR or valve in valve transcatheter aortic valve replacement (ViV-TAVR), in Trifecta versus other bioprosthetic valves. Patients who underwent Redo-AVR for SVD at our institution were categorized into two groups based on valve type: Trifecta vs non-Trifecta...
April 3, 2024: American Journal of Cardiology